Bear Mountain Capital’s Genmab GMAB Stock Holding History

Bear Mountain Capital’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6	Closed	-$181	–	248
2025 Q3	$181	Buy	+6	New	+$146	﹤0.01%	277

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bear Mountain Capital's GMAB Position: Q4 2025 in Review

Bear Mountain Capital sold out of Genmab (GMAB) in Q4 2025, closing a stake of 6 shares — an estimated $181 sold.

Bear Mountain Capital first reported a position in GMAB in Q3 2025 and held it in 1 quarter. The position peaked at $181 in Q3 2025. 293 funds tracked by Wall St. Rank hold GMAB as of Q4 2025.

Bear Mountain Capital reported no remaining Genmab position as of Q4 2025 after selling out during the quarter.
Bear Mountain Capital sold 6 Genmab shares in Q4 2025, an estimated $181.
Bear Mountain Capital first reported a position in Genmab in Q3 2025 and held it in 1 quarter.
Bear Mountain Capital's Genmab position peaked at $181 in Q3 2025.
293 funds tracked by Wall St. Rank held Genmab as of Q4 2025.

Based on Bear Mountain Capital's 13F filing for Q4 2025, filed 22 Jan 2026.